Tag: organs

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

CHICAGO, June 17, 2025 /PRNewswire/ -- The Global Medical Biomimetics Market is projected to be valued at USD 35.68 billion in 2024 and reach USD 55.36 billion by 2030, growing...

Perfusion Medical Announces Scholarship from Virginia Bio to Participate in 2025 BIO International Convention

RESTON, Va., June 16, 2025 /PRNewswire/ -- Perfusion Medical, an emerging biopharmaceutical company developing a pipeline of life-saving, acute cardiovascular therapies to transform intensive...

Regenerative Medicine Market to Hit USD 115.6 Billion by 2029 | Rising Demand in Dermatology & Orthopedic Fuels 19.2% CAGR | Valuates Reports

BANGALORE, India, June 16, 2025 /PRNewswire/ -- Regenerative Medicine Market is Segmented by Type (Cell Therapy, Tissue Engineering, Biomaterial), by Application (Dermatology, Cardiovascular, CNS, Orthopedic). The...

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsOrgans

Robbins LLP Reminds CVLT Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action...

Teen-Founded Nonprofit Busy Buzzy Bots Reaches 11,000+ Kids Through STEM Education–and It Is Just Getting Started

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

Tag: organs

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

Perfusion Medical Announces Scholarship from Virginia Bio to Participate in 2025 BIO International Convention

Regenerative Medicine Market to Hit USD 115.6 Billion by 2029 | Rising Demand in Dermatology & Orthopedic Fuels 19.2% CAGR | Valuates Reports

Samsung Biologics launches drug screening services, Samsung Organoids

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us